Business
ProAxsis is awarded a European CE Mark
ProAxsis is awarded a European CE Mark.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 6606P NetScientific PLC 04 September 2017 \n\nNetScientific plc\n(\"NetScientific\" or the \"Company\" or the \"Group\")\n \nProAxsis is awarded a European CE Mark for their NEATstik® point-of-care lung inflammation monitoring test \n \nLondon, UK - September 4th 2017 - NetScientific plc (\"NetScientific\", AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces an update for its portfolio company, ProAxsis. ProAxsis today announced that the product development process for NEATstik®, a novel point-of-care test for measuring active neutrophil elastase, is complete and, having successfully registered the product with a CE Mark, ProAxsis is now able to initiate sales of the NEATstik® throughout Europe.\n \nCommenting on the news, Francois Martelet, Chief Executive Officer of Netscientific and Chairman of ProAxsis, said: \"We are very excited to announce that ProAxsis has successfully completed the development phase of its lead product, the NEATstik® which utilises the company's novel ProteaseTag® technology. We believe the award of the CE mark represents a pivotal moment for the commercial development of ProAxsis and will catalyse sales and therefore near term value creation for the group.\"\n \nNetScientific holds a 57% stake on a fully diluted basis in ProAxsis.\n \nThe full text of the announcement from ProAxsis can be found below.\n \n# # #\n \nFor more information, please contact:\n \n\n\n\n\n NetScientific\n François R. Martelet, M.D., CEO\n Ian Postlethwaite, CFO\n\n\nTel: +44 (0)20 3514 1800\n\n\n\n\n \n Consilium Strategic Communications\n Mary-Jane Elliott Jessica Hodgson /\n Chris Welsh / Laura Thornton \n \n\n\n \nTel: +44 (0)20 3709 5700\[email protected]\n\n\n\n\nStifel Nicolaus Europe Limited (NOMAD and Broker)\nJonathan Senior / David Arch / Ben Maddison\n\n\n Tel: +44 (0) 20 7710 7600\n\n\n\n\n \n \nProAxsis registers European CE Mark for first neutrophil elastase point-of-care test\nDate: September 4th, 2017\nProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care test for measuring active neutrophil elastase, and has successfully registered the product with a C...